藤井 清永

藤井 清永FUJII Kiyonaga

薬学部 漢方薬学科／分析化学分野

• 学位

  博士（薬学）

• 所属学会

  日本薬学会、日本癌学会、日本分析学会、日本質量分析学会

• 専門分野

  分析化学、プロテオミクス

• 研究テーマ

  分析化学、特に分離分析、質量分析に特化した、生体分子および医薬品に対する分析手法の開発とその応用

業績

• （原著論文）

  1. Yokoo H, Shibata N, Naganuma M, Murakami Y, Fujii K, Ito T, Aritake K, Naito M, Demizu Y. Development of a hematopoietic prostaglandin D synthase-degradation inducer. ACS Med Chem Lett. 2021 Jan 14;12(2):236-241. PMID: 33603969

  2. Ooshio T, Yamamoto M, Fujii K, Xin B, Watanabe K, Goto M, Okada Y, Suzuki A, Penninger JM, Nishina H, Nishikawa Y. Hepatocyte MKK7 contributes to restoration of the liver parenchyma following injury. Hepatology. 2021 Jun;73(6):2510-2526. PMID: 32969030

  3. Nishimura T, Nakamura H, Tan KT, Zhuo DW, Fujii K, Koizumi H, Naruki S, Takagi M, Furuya N, Kato Y, Chen SJ, Kato H, Saji H. A proteogenomic profile of early lung adenocarcinomas by protein co-expression network and genomic alteration analysis. Sci Rep. 2020 Aug 12;10(1):13604. PMID: 32788598 Free PMC article.

  4. Nishimura T, Nakamura H, Yachie A, Hase T, Fujii K, Koizumi H, Naruki S, Takagi M, Matsuoka Y, Furuya N, Kato H, Saji H. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Sci Rep. 2020 Jul 2;10(1):10881. PMID: 32616892 Free PMC article.

  5. Nakamura H, Fujii K, Gupta V, Hata H, Koizumu H, Hoshikawa M, Naruki S, Miyata Y, Takahashi I, Miyazawa T, Sakai H, Tsumoto K, Takagi M, Saji H, Nishimura T. Identification of key modules and hub genes for small-cell lung carcinoma and large-cell neuroendocrine lung carcinoma by weighted gene co-expression network analysis of clinical tissue-proteomes. PLoS One. 2019 Jun 5;14(6):e0217105. PMID: 31166966

  6. Watanabe K, Yamamoto M, Xin B, Ooshio T, Goto M, Fujii K, Liu Y, Okada Y, Furukawa H, Nishikawa Y. Emergence of the dedifferentiated phenotype in hepatocyte-derived tumors in mice: roles of oncogene-induced epigenetic alterations. Hepatol Commun. 2019 Feb 25;3(5):697-715. PMID: 31061957

  7. Fujii K, Miyata Y, Takahashi I, Koizumi H, Saji H, Hoshikawa M, Takagi M, Nishimura T, Nakamura H. Differential proteomic analysis between small cell lung carcinoma (SCLC) and pulmonary carcinoid tumors reveals molecular signatures for malignancy in lung cancer. Proteomics Clin Appl. 2018 Nov;12(6):e1800015. PMID: 29888431

  8. Yamamoto M, Xin B, Watanabe K, Ooshio T, Fujii K, Chen X, Okada Y, Abe H, Taguchi Y, Miyokawa N, Furukawa H, Nishikawa Y. Oncogenic determination of a broad spectrum of phenotypes of hepatocyte-derived mouse liver tumors. Am J Pathol. 2017 Dec;187(12):2711-2725. PMID: 28964793

  9. Xin B, Yamamoto M, Fujii K, Ooshio T, Chen X, Okada Y, Watanabe K, Miyokawa N, Furukawa H, Nishikawa Y. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. Oncogene. 2017 Sep 7;36(36):5087-5097. PMID: 28481866 Free PMC Article

  10. Fukuda T, Nomura M, Kato Y, Tojo H, Fujii K, Nagao T, Bando Y, Fehniger TE, Marko-Varga G, Nakamura H, Kato H, Nishimura T. A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references. PLoS One. 2017 Apr 27;12(4):e0176219. PMID: 28448532 Free PMC Article

• （総説等）

  1. Fujii K, Nakamura H, Nishimura T. Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma. Expert Rev Proteomics. 2017 Apr;14(4):373-386. PMID: 28271730

• （特許出願・取得）

  1. がんの治療又は予防剤、及びがんの治療又は予防のためのＲＦ経路阻害剤とＭＥＫ阻害剤との組み合わせ（特許出願2021-029585）

• （競争的資金獲得状況）

  1. 科学研究費補助金（基盤研究C）「リボフラビン経路を標的とした新規膵臓がん治療法の開発」（分担）

  2. 科学研究費補助金（基盤研究B）「膵臓がんの頑健性の分子基盤の解明とその破壊による新規治療法の確立」（分担）

• （社会貢献）

  1. 日本分析化学会 九州支部・幹事

  2. 日本薬学会 九州山口支部・幹事